Company profile for Viking Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. Viking has exclusive worldwide rights to a portfolio of five therapeutic pro...
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
12340 El Camino Real, Suite 250 San Diego, CA 92130
Telephone
Telephone
858-704-4660
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-the-piper-sandler-37th-annual-healthcare-conference-302625822.html

PR NEWSWIRE
25 Nov 2025

https://www.prnewswire.com/news-releases/viking-therapeutics-announces-completion-of-enrollment-in-phase-3-vanquish-1-trial-of-vk2735-302619296.html

PR NEWSWIRE
19 Nov 2025

https://www.prnewswire.com/news-releases/viking-therapeutics-highlights-clinical-data-from-vk2735-obesity-program-in-presentation-at-obesityweek-2025-302606589.html

PR NEWSWIRE
06 Nov 2025

https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302602732.html

PR NEWSWIRE
05 Nov 2025

https://www.prnewswire.com/news-releases/viking-therapeutics-to-highlight-clinical-data-from-vk2735-obesity-program-in-presentations-at-obesityweek-2025-302597590.html

PR NEWSWIRE
30 Oct 2025

https://www.prnewswire.com/news-releases/viking-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update-302591893.html

PR NEWSWIRE
22 Oct 2025

Excipients

Click here to find the perfect excipient manufacturers by their capabilities

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty